How are synthetic peptides manufactured?
Synthetic peptides are manufactured by solid-phase peptide synthesis (SPPS) — a sequential coupling process that builds the peptide chain one amino acid at a time on a solid-support resin, then cleaves the completed peptide from the resin for purification. The dominant manufacturing method for research and pharmaceutical peptide products under ~50 residues.
What the research literature says
The solid-phase peptide synthesis (SPPS) framework was developed by Bruce Merrifield in the 1960s. The synthesis begins by attaching the C-terminal amino acid (with its side-chain protected) to an insoluble resin bead. Subsequent amino acids are added sequentially via cycles of N-terminal deprotection, activated coupling, and washing — each cycle adds one residue to the growing peptide chain. After completing the sequence, the peptide is cleaved from the resin with simultaneous side-chain deprotection, then purified by reversed-phase HPLC.
Two SPPS chemistries dominate: Fmoc/tBu (using fluorenylmethyloxycarbonyl protecting groups, base-labile, mild conditions) and Boc/Bzl (using tert-butyloxycarbonyl protecting groups, acid-labile, requires HF cleavage at the end). Fmoc is the more common contemporary chemistry due to milder conditions; Boc is used for specific peptide sequences that require it.
Larger peptides (above ~50 residues) are produced by chemical ligation strategies that join two solid-phase-synthesised fragments, or by recombinant expression in bacterial or yeast hosts. Native chemical ligation, expressed protein ligation, and similar fragment-coupling approaches extend the size range accessible via synthetic-chemistry routes beyond the practical SPPS limit.
Why this matters in research context
SPPS matters in peptide-research contexts as the manufacturing context underlying every catalog peptide. Researchers don’t typically need to understand SPPS in detail to use peptide products, but the framework anchors the impurity-profile expectations on a credible peptide COA — sequence-variants, deletion peptides (missing one residue), and incomplete-deprotection impurities are the canonical SPPS-derived impurity classes that appear on HPLC chromatograms.
Related compounds
- Certificate of analysis (glossary entry) — impurity-profile interpretation
Related research questions
References
- ICH Q7 — Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Covers peptide-product manufacturing under cGMP. International Council for Harmonisation.
- USP <1086> Impurities in Drug Substances and Drug Products. Covers SPPS-derived impurity classes. United States Pharmacopeia.
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.